drugset / Trial / NCT01927718
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if adding low dose Thalidomide (thalidomide) to Revlimid (lenalidomide) maintenance therapy will help control MM after an autologous stem cell transplant. Researchers also want to learn if treatment with these study drugs will improve participants' quality of life.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-11
- Completion
- 2016-11
Outcome
Outcome not reported
Stopped: “Poor Response Rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |